Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Annelise Capossela/Axios

House Democrats are following the money in a series of new ads hitting Republican opponents of major drug price legislation — but the trail also leads back to their own members.

What's happening: The Democratic Congressional Campaign Committee is accusing House Republicans of doing the bidding of drug industry donors by opposing the bill. Unremarked upon are the House Democrats who've also received money from the industry — and whose opposition is seen as potentially fatal to the legislation.

The big picture: The DCCC leveled the allegations in a new round of digital ads unveiled Tuesday. They take Republicans to task for opposing a bill that would effectively cap drug prices.

  • The campaign is a response to recent ads by the GOP-aligned American Action Network hitting Democrats for supporting the legislation. The group has received funding from the Pharmaceutical Research and Manufacturers of America, the drug industry's largest trade group.
  • The DCCC pegged the line of attack to a recent report from the House Oversight Committee, which found the company AbbVie dramatically raised prices for a number of drugs while it hiked executive pay. AbbVie is also a high-dollar contributor to PhRMA.
  • "Unlike Republicans," the DCCC declared in a news release on its ads, "House Democrats aren’t going to bow down to Big Pharma and will continue fighting to lower the costs of prescription drugs."

Between the lines: The Democrats are not quite as united as that statement makes it sound. Ten members recently sent a letter to House Speaker Nancy Pelosi (D-Calif.) expressing concerns about the drug pricing legislation as written.

  • Democrats currently have an eight-seat majority in the House, meaning 10 defections could doom the legislation.
  • Of those 10 members, seven got contributions last cycle from PhRMA, according to Federal Election Commission records. Six received donations from AbbVie's political action committee.
  • The DCCC did not respond to requests for comment about those donations in the context of its new ads.

Be smart: The pharmaceutical industry's D.C. presence is massive, and it gives handily to legislators of both parties.

  • That provides Democrats and Republicans with plenty of opportunities to knock the other side for cronyism.
  • It also can leave colleagues vulnerable to friendly fire.

Go deeper

Jan. 6 select committee elevates Liz Cheney to vice chair

Photo: Andrew Harnik/Pool via Xinhua via Getty Images

Rep. Bennie Thompson (D-Miss.), the chair of the House select committee in charge of investigating the Jan. 6 Capitol insurrection, announced Thursday that he has named Rep. Liz Cheney (R-Wyo.) as vice chair.

Why it matters: Cheney, who was already the committee's top Republican, is now the panel's second-ranking member, an unusual move for a committee dominated by Democrats due to House GOP leadership's refusal to participate.

Mike Allen, author of AM
2 hours ago - Politics & Policy

GOP senator calls for senility test for aging leaders

Photo: "Axios on HBO"

Sen. Bill Cassidy (R-La.), a physician, told me during an "Axios on HBO" interview that he favors cognition tests for aging leaders of all three branches of government.

Why it matters: Wisdom comes with age. But science also shows that we lose something. And much of the world is now run by old people — including President Biden, 78 ... Speaker Pelosi, 81 ...  Senate Majority Leader Chuck Schumer, 70 ... and Senate Minority Leader Mitch McConnell, 79.

Ina Fried, author of Login
2 hours ago - Technology

Intel CEO blames predecessors for manufacturing woes

Axios on HBO

When it comes to Intel's recent manufacturing problems, Intel CEO Pat Gelsinger places the blame squarely on his predecessors — many of whom he notes were not engineers deeply steeped in chip technology, as he is.

Why it matters: Gelsinger has announced a broad plan to reinvigorate Intel by doubling down on manufacturing. However, the strategy depends on the venerable semiconductor giant recovering from recent stumbles.